Over the last decade, the number of clinical trials involving recombinant adeno-associated viral (AAV) vectors has dramatically increased, the diversity of serotypes has expanded and the demand for larger quantities of highly purified material manufactured to cGMP standards has rocketed.
- Establish an AAV production platform
- Implement one single chromatography media to purify various AAV stereotypes